



METHODS AND TECHNIQUES FOR ASSESSING **EXPOSURE** TO **ANTIMALARIAL DRUGS** IN CLINICAL FIELD STUDIES

INFORMAL CONSULTATION ORGANIZED BY THE
WORLD HEALTH ORGANIZATION WITH THE TECHNICAL SUPPORT
OF THE WORLDWIDE ANTIMALARIAL RESISTANCE NETWORK

22-24 FEBRUARY 2010, BANGKOK, THAILAND



**World Health
Organization**



METHODS AND TECHNIQUES FOR ASSESSING **EXPOSURE** TO **ANTIMALARIAL DRUGS** IN CLINICAL **FIELD STUDIES**

INFORMAL CONSULTATION ORGANIZED BY THE
WORLD HEALTH ORGANIZATION WITH THE TECHNICAL SUPPORT
OF THE WORLDWIDE ANTIMALARIAL RESISTANCE NETWORK

22-24 FEBRUARY 2010, BANGKOK, THAILAND



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data :

Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies.

1.Antimalarials - blood. 2.Antimalarials - therapeutic use. 3.Antimalarials - pharmacokinetics. 4.Artemisinins - therapeutic use. 5.Malaria - drug therapy. I.World Health Organization. II.Informal consultation organized by the World Health Organization with the technical support of the worldwide antimalarial resistance network.

ISBN 978 92 4 150206 1

(NLM classification: QV 256)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the report of an informal consultation and does not necessarily represent the decisions or policies of the World Health Organization.

Editing: Elisabeth Heseltine

Design: elfiga.ch

Layout coordination: Claudia Corazzola, WHO Graphics

Cover: Denis Meissner, WHO Graphics

Printed in France

Contents

Acknowledgements	5
Abbreviations	6
Introduction	7
Chapter 1.	
Analytical strategies	11
1.1 Overview	11
1.2 Sample preparation	12
1.3 Measurement	14
1.4 Methods for measuring antimalarial drug concentrations	20
1.5 Recommendations	21
1.6 Rationale	23
Appendix 1. Assay conditions for measuring antimalarial agents in various matrices	25
Chapter 2.	
Pre-analytical variables in antimalarial drug assays	41
2.1 Overview	41
2.2 Biological matrices	41
2.3 Sampling containers	42
2.4 Food intake	42
2.5 Anticoagulants and stabilizers	42
2.6 Haemolysis	43
2.7 Drug concentrations in different matrices	43
2.8 Transport and storage of samples to maintain stability	51
2.9 Recommendations	57
2.10 Rationale	59
Chapter 3.	
Optimizing sampling schemes for pharmacokinetics studies	61
3.1 Clinical indications for measuring antimalarial drug concentrations in blood	61
3.2 Covariates that affect the pharmacokinetics of antimalarial drugs	68
3.3 Sampling schemes for pharmacokinetics studies	70
3.4 Optimal design methods	72
3.5 Simplified measurement of exposure to a drug	73
3.6 Recommendations for intensive strategies	75
3.7 Recommendations for population pharmacokinetics strategies	78

3.8	Rationale for suggested time windows	80
3.9	Recommendations for simplified measurement of exposure to antimalarial drugs	80
3.10	Rationale for recommended simplified measurement of drug exposure	80
Appendix 2.	Suggested sampling windows for population pharmacokinetics studies of antimalarial drugs	81

Chapter 4.

Validation strategies		95
4.1	Validation according to international guidelines	95
4.2	Types of method validation	98
4.3	Standard reference material	100
4.4	Preparation of standards and quality controls	101
4.5	Accuracy and precision	102
4.6	Linearity and range	103
4.7	Selectivity	104
4.8	Sensitivity	104
4.9	Recovery	104
4.10	Stability studies	105
4.11	Carryover	108
4.12	Haemolysis and lipaemia	108
4.13	Validation aspects of mass spectrometric assays	109
4.14	Incurred sample re-analysis	110
4.15	Dried blood spots	111
4.16	Recommendations	112
4.17	Rationale	116

Chapter 5.

Implementation of methods for the analysis of clinical samples		117
5.1	Acceptance criteria in routine analysis	117
5.2	Timing of sample re-analysis	121
5.3	Corrective action requests	121
5.4	Benefit of external quality assurance schemes	122
5.5	Bioanalytical record-keeping and reports	123
5.6	Examples of bioanalytical study records	125
5.7	Final analytical reports	126
5.8	Data archiving	127
5.9	Equipment verification	127
5.10	Recommendations	127
5.11	Rationale	128

References		129
-------------------	--	-----

List of participants		161
-----------------------------	--	-----

Acknowledgements

This technical guidance document would not have been possible without the experience and knowledge of Niklas Lindegardh, who coordinated the consensus meeting and contributed to all parts of the document. Jennifer Norman served as the rapporteur for the meeting and compiled the guidance.

The following contributed to the document as lead writers, contributing writers and peer reviewers:

Chapter 1: William Watkins (Chair), Fraction Dzinjalamala, Michael Green, Michael Kozar

Chapter 2: Yngve Bergqvist (Chair), Grace Sola Gbotosho, Vincent Jullien, Kesara Na-Bangchang

Chapter 3: Julie Simpson (Chair), Michael Ashton, Karen Barnes, Kasia Stepniewska, Joel Tarning, Nicholas White

Chapter 4: Niklas Lindegardh (Chair), Michael Douglas Edstein, Lawrence Fleckenstein, Stephen Ward

Chapter 5: Peter John Smith (Chair), Michael Douglas Edstein, Jennifer Norman, Lubbe Joachim Wiesner

The following contributed to the consensus discussions and reviewed the final document: Nicholas Day, Arjen Dondorp, Philippe Guérin, Warunee Hanpithakpong, Thomas Kanyok, Qigui Li, Sharif Mahsufi Mansor, Myaing Myaing Nyunt, Gerson Pianetti, Pascal Ringwald, David Saunders, Paktiya Teja-Isavadharm.

Acknowledgments are also due to the Bill & Melinda Gates Foundation for its financial support towards convening the consensus meeting.

For more information, please contact:

Dr Pascal Ringwald
Drug Resistance and Containment Unit
Global Malaria Programme
World Health Organization
20 avenue Appia
1211 Geneva 27
Switzerland
Tel.: +41 22 791 3469
Fax: +41 22 791 4824
E-mail: ringwaldp@who.int

Abbreviations

AUC	area under the concentration–time curve
DBS	dried blood spot
EDTA	ethylenediaminetetraacetic acid
HPLC	high-performance liquid chromatography
ISR	incurred sample re-analysis
LC	liquid chromatography
LLOQ	lower limit of quantification
MS	mass spectrometry
MS/MS	tandem mass spectrometry
PK	pharmacokinetics
RBC	red blood cell
ULOQ	upper limit of quantification
UV	ultraviolet radiation
WHO	World Health Organization

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?r>